Replimune Group, Inc. $REPL Shares Sold by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. reduced its stake in Replimune Group, Inc. (NASDAQ:REPL) by 32.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,808,368 shares of the company’s stock after selling 1,350,000 shares during the quarter. Replimune Group accounts for 3.6% of Fcpm Iii Services B.V.’s portfolio, making the stock its 7th biggest position. Fcpm Iii Services B.V.’s holdings in Replimune Group were worth $27,297,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Persistent Asset Partners Ltd acquired a new position in Replimune Group in the fourth quarter valued at approximately $598,000. Squarepoint Ops LLC boosted its stake in Replimune Group by 22.3% in the fourth quarter. Squarepoint Ops LLC now owns 67,271 shares of the company’s stock valued at $654,000 after acquiring an additional 12,264 shares during the period. Entropy Technologies LP acquired a new position in Replimune Group in the fourth quarter valued at approximately $102,000. Marshall Wace LLP acquired a new position in Replimune Group in the fourth quarter valued at approximately $910,000. Finally, Hudson Bay Capital Management LP acquired a new position in Replimune Group in the fourth quarter valued at approximately $1,493,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on REPL shares. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 target price for the company in a research note on Friday, May 29th. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Friday, April 10th. BMO Capital Markets downgraded Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Seven equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Replimune Group presently has an average rating of “Reduce” and a consensus price target of $4.88.

Replimune Group Stock Performance

REPL opened at $8.78 on Wednesday. The business’s 50 day moving average is $5.27 and its 200-day moving average is $7.25. The stock has a market cap of $724.96 million, a PE ratio of -2.55 and a beta of 0.91. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $13.24.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.